New hope for kids with neuroblastoma? early trial tests targeted radiation
NCT ID NCT03966651
First seen Nov 18, 2025 · Last updated Jun 18, 2026 · Updated 29 times
Summary
This early-phase study tested a type of radiation therapy called PRRT in children whose neuroblastoma had come back or did not respond to standard treatments. The goal was to find the safest dose of the radioactive drug 177Lu-DOTATATE. Only one child took part, and the study focused on safety and side effects, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Angers
Angers, France
-
CHU Besançon
Besançon, France
-
CHU Dijon
Dijon, France
-
CHU Nancy
Nancy, France
-
CHU Nantes
Nantes, France
-
CHU Pellegrin
Bordeaux, France
-
CHU Reims
Reims, France
-
CHU Strasbourg
Strasbourg, France
-
CHU de Grenoble
Grenoble, France
-
CHU de Toulouse - Hôpital des enfants
Toulouse, France
-
Centre Léon Bérard
Lyon, France
-
Centre Oscar Lambret
Lille, France
-
Hopital Arnaud de Villeneuve
Montpellier, France
-
IUCT-O
Toulouse, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.